Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
Eli Lilly and Company (LLY) EPS (diluted)
Eli Lilly and Company's EPS (diluted) for fiscal 2025 was $22.95, up 96.0% from $11.71 in fiscal 2024. Over the twelve months to 30 June 2026 it was $29.80. Over the past ten years it has ranged from −$0.19 (fiscal 2017) to $22.95 (fiscal 2025) — the current reading is the highest in ten years. Eli Lilly and Company ranks 1st of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $22.95 | 95.99% |
| FY2024 | $11.71 | 101.90% |
| FY2023 | $5.80 | (15.94%) |
| FY2022 | $6.90 | 12.75% |
| FY2021 | $6.12 | (9.87%) |
| FY2020 | $6.79 | (23.62%) |
| FY2019 | $8.89 | 184.03% |
| FY2018 | $3.13 | — |
| FY2017 | −$0.19 | — |
| FY2016 | $2.58 | 14.16% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $7.94 | (3.87%) |
| Mar 2026 | $8.26 | 11.77% |
| Dec 2025 | $7.39 | 19.00% |
| Sep 2025 | $6.21 | (1.27%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LLY Eli Lilly and Company | $29.80 |
| AMGN Amgen Inc. compare | $16.09 |
| JNJ Johnson & Johnson compare | $8.63 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| ABBV AbbVie Inc. compare | $3.54 |
| MRK Merck & Co., Inc. compare | $1.25 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on LLY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement